Search

Displaying results 4751 - 4760 of 10000 in total
  1. Drug

    KP-1461

    go.drugbank.com/drugs/DB05644
    Investigational

    KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. … Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.

  2. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    [Infergen] is a bio-engineered type I interferon alpha that is FDA-approved for the treatment of patients with chronic hepatitis C infections. … PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small

    Synonyms: PEG INF alfacon-1
  3. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.[A39048]

    Categories: Topoisomerase II Inhibitors
  4. Drug

    Apadenoson

    go.drugbank.com/drugs/DB05009
    Investigational

    Apadenoson is a selective A2a adenosine receptor agonist designed for use as a pharmacologic stress agent in cardiac perfusion imaging studies. … It is developed by Bristol-Myers Squibb and is in phase II of clinical trials.

    Categories: Adenosine A receptor agonists
  5. Drug

    NV-07a

    go.drugbank.com/drugs/DB05845
    Experimental

    NV-07a is topical skin repair compound protecting skin from sun-induced immunosuppression and UV-induced damage.

  6. Drug

    Pozanicline

    go.drugbank.com/drugs/DB05458
    Investigational

    ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity … In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes.

  7. Drug

    SL017

    go.drugbank.com/drugs/DB05156
    Experimental

    SL017 formulated as a topical gel, has been combined with a widely available light source for permanent removal of unwanted hair and for treatment of actinic keratosis

  8. Drug

    Tandutinib

    go.drugbank.com/drugs/DB05465
    Investigational

    Tyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. … MLN518 is a novel, oral, small molecule designed to inhibit type III receptor tyrosine kinases, including FLT3, (platelet-derived growth-factor receptor) PDGFR and c-KIT.

  9. Drug

    Proxalutamide

    go.drugbank.com/drugs/DB16065
    Investigational

    Proxalutamide is under investigation in clinical trial NCT03899467 (The Safety and Tolerability of Proxalutamide (GT0918) in Subjects With Metastatic Castrate Resistant Prostate Cancer).

  10. Drug

    beta-Hydroxybutyric acid

    go.drugbank.com/drugs/DB16506
    Investigational

    Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236